Follicular lymphoma (FL) is a type of blood cancer and a form of non-Hodgkin's lymphoma. Thanks to new treatment breakthroughs, about 80% of FL patients have a survival rate of more than 10 years. The other 20%, however, ...
Mar 31, 2026
0
6
Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections and tumors. For these processes to function properly, immune cells (B cells and T cells) must be ...
Mar 25, 2026
0
4
Twenty years. That's how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of Rochester's Wilmot Cancer Institute. And he isn't alone: 70% of patients in the trial who had advanced-stage ...
Mar 1, 2026
0
26
New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, ...
Dec 8, 2025
0
10
In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard ...
Dec 8, 2025
0
11
A new study from Karolinska Institutet, published in Cell Reports Medicine, shows that follicular lymphoma (FL), a common type of blood cancer, is not one single disease but consists of three genetically distinct subtypes. ...
Aug 15, 2025
0
31
In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts, a phenomenon they describe ...
Aug 12, 2025
0
18
Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the proliferation and apoptosis of ...
Jul 9, 2025
0
17
The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Jun 23, 2025
0
14
Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone lymphoma.
Dec 9, 2024
0
47
